LaVoieHealthScience Continues to Add to Public Company Client Roster

LaVoieHealthScience Continues to Add to Public Company Client Roster

Integrity Applications and Savara Pharmaceuticals Join LHS Portfolio of PR/IR Clients

Boston, MA – November 9, 2017 — LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced two additional public company clients, Integrity Applications and Savara Pharmaceuticals. These clients join a prestigious group of innovative health and science companies that are represented by LHS for their investor and/or public relations solutions.

Integrity Applications (OTCMKTS: IGAP), founded in 2001 and is focused on the design, development, and commercialization of non-invasive glucose monitoring technologies for people with type 2 diabetes and prediabetes. The company has developed GlucoTrack®, a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements in about a minute without the pain, incremental cost, difficulty, or discomfort of conventional invasive finger stick devices.

Savara Pharmaceuticals (NASDAQ: SVRA), went public through a reverse merger with Mast Therapeutics in 2017. Based in West Lake Hills, TX, Savara is an emerging pharmaceutical development company focused on advancing a pipeline of novel inhalation therapies for the treatment of patients with rare pulmonary conditions. Savara has three investigational products in various stages of clinical development: Molgradex, the first inhaled product being developed for the treatment of patients with Pulmonary Alveolar Proteinosis and Nontuberculous Mycobacterial (NTM) Lung Infection; AeroVanc, an inhaled dry powder form of vancomycin to treat Methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis patients; and Aironite, which is inhaled via nebulizer to treat heart failure patients with preserved ejection fraction. Savara has an affiliate company based in Hørsholm, Denmark.

“Our integrated public and investor relations offerings, building on our team’s expertise is validated by these new client wins,” said Donna L. LaVoie, President & CEO of LaVoieHealthScience. “Each client has very specific business objectives in which our industry-tested strategic communications programs are being implemented. Aligning with true innovators in the health and science field is our passion.”

About LaVoieHealthScience
LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides strategic communications, investor relations and public relations to build recognition and increase sales and value for health science innovations. The agency has received 29 awards over the past seven years in recognition of the work it has done for its health and science industry-leading clients, and is ranked among the 2017 Inc. 5000 list of fastest growing private companies for the fourth year. In addition to clients listed above, LaVoieHealthScience represents leaders such as Biotechnology Innovation Organization, Fusion Pharmaceuticals, Iota BioSciences, Landos Biopharma, LEO Science Hub, NewLink Genetics, Newron Pharmaceuticals, Origenis, Xontogeny LLC and other emerging health and science companies.

###

Media Contact:
Ryan Donovan
rdonovan@lavoiehealthscience.com
617-374-8800 x102

Coordinating Messages When Companies Join Forces

Click the image to read more.

By Donna LaVoie

Life science companies, including big and small pharma, biotech and health technology, continue the trend toward partnerships to research, develop and/or commercialize their innovations, allowing companies to enter new markets, continue niche disease research and development and introduce innovations sooner. Adding to the mix are accelerators and venture firms launching new companies into the health science and technology ecosystem.

Even though they are joining forces, and likely have the same end-goal, each of these companies will have a unique, and sometimes competing, set of communications and business goals. They also may have different priorities on stakeholder mix. While it’s easy to default to the needs of the larger company, strategic communications entails finding ways to balance the needs of all parties in the transaction.

Read more at O’Dwyer’s.

LaVoieHealthScience Adds Former Analyst & Welcomes New PR & IR Clients

LaVoieHealthScience Adds Former Analyst, Chiara Russo to Its Investor Relations Team

Welcomes New PR & IR Clients to its Roster

…LHS Makes Inc. 5000 List for 4th Time

 

Boston, MA – August 24, 2017 —  LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced that former specialty pharmaceutical analyst, Chiara Russo joined the LHS team as Director, Investor Relations. In addition, LHS announced new clients, the life science accelerator, Xontogeny LLC and electroceutical pioneer, Iota BioSciences.

Ms. Russo joins LHS from Cantor Fitzgerald, LLC, where she was Director, Research Analyst covering various small to mid-cap specialty pharma/biotech companies across a multitude of therapeutic areas leading to a significant industry network.  She has been quoted in many news outlets such as Bloomberg, Reuter, TheStreet and Bezinga and accompanied company executives on numerous non-deal roadshows in major investor centers.  Prior to her role at Cantor, Chiara was Vice President, Research Analyst at Janney Montgomery Scott, LLC, having started her career at Think Equity LLC.

“Continuing to add experienced health and science communications talent to our team is an important part of our strategy for growth,” said Donna L. LaVoie, President & CEO of LaVoieHealthScience. “With our continued focus in providing an integrated solution in both investor and public relations to our clients, adding Chiara to the team provides us with additional bench strength in IR and financial communications.”

“I am excited to already be applying my skills as an analyst to help LHS’ clients with story-telling and their investment thesis along with an insider’ view on how news is viewed and potential institutional targets,” said Russo.

Xontogeny LLC, founded by former Sarepta CEO and serial entrepreneur, Chris Garabedian, is a biotech aggregator that supports the accelerated development of life science technologies in the pursuit of helping patients with serious diseases.  Xontogeny partners with entrepreneurs, providing the leadership and operating experience needed to increase the probability of success with early drug and technology development.

Iota BioSciences, founded in Berkeley, CA, is an emerging electroceutical company revolutionizing the use of “vanishingly small” wireless, battery less sensors, bringing closer a time when a Fitbit-like device could monitor internal nerves, muscles, or organs in real time.

“As this is our fourth time making the Inc. 5000 fastest-growing private company list, we are proud of the team’s accomplishments and to add these clients to our list of movers and shakers in the health and sciences field,” said Donna LaVoie, President & CEO of LaVoieHealthScience. “The LHS team is excited to help these emerging health and science innovators add value and grow.”

About LaVoieHealthScience

LaVoieHealthScience partners with leading life science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides strategic communications, investor relations and public relations to build recognition and increase sales and value for health science innovations. The agency has received 29 awards over the past seven years in recognition of the work it has done for its health and science industry-leading clients, and is ranked among the 2017 Inc. 5000 list of fastest growing private companies for the fourth year. In addition to clients listed above, LaVoieHealthScience represents leaders such as Biotechnology Innovation Organization, Cydan Development, Imara, NewLink Genetics, Newron Pharmaceuticals, Origenis, and other emerging health and science companies.

###

Contact:
Beth Kurth
Vice President, Investor Relations
bkurth@lavoiehealthscience.com
617-374-8800 x106

LaVoieHealthScience Clients Recognized by Xconomy

 LaVoieHealthScience Clients Recognized by Xconomy

LEO Science & Tech Hub and Xontogeny Selected as Award Finalists

LaVoieHealthScience, an integrated investor and public relations agency focused on advancing health and science innovations, today announced that two clients, LEO Science & Tech Hub and Xontogeny are finalists for the 2017 Xconomy awards!  The Xconomy awards honor the top people, companies and organizations that make the Boston life sciences community one of the most vibrant innovation centers in the world during Biotech Week Boston.

Chris Garabedian, CEO of Xontogeny is a finalist in the Contrarian category and LEO Science & Tech Hub in the Newcomer category.

The Xconomy Awards are part of the Biotech Week in Boston and will be presented at the awards gala on September 26th.

About LaVoieHealthScience

LaVoieHealthScience partners with leading life science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides strategic communications, investor relations and public relations to build recognition and increase sales and value for health science innovations. The agency has received 28 awards over the past seven years in recognition of the work it has done for its health and science industry-leading clients. In addition to clients listed above, LaVoieHealthScience represents leaders such as Cydan Development, Imara, NewLink Genetics, Biotechnology Innovation Organization, Newron Pharmaceuticals, Origenis, and other emerging health and science companies.

Donna LaVoie to Present “The LHS Fifteen-Slide Presentation®” at Venture Cafe

You’re Invited: “The LHS Fifteen-Slide Presentation®

Venture Café at The Cambridge Innovation Center (CIC)

Thursday, August 24, 5:30 – 6:30 p.m.

 

You are invited to join Donna LaVoie, President & CEO of LaVoieHealthScience, for her trademarked workshop “The LHS Fifteen-Slide Presentation®” on August 24 from 5:30-6:30 pm ET at the Venture Cafe, One Broadway, Kendall Square, Cambridge. First presented at BIO International in 2016, the workshop was offered again in 2017 to a standing-room-only crowd and is now available on the East Coast!

This workshop covers how to create an engaging company presentation in just 15 slides.   At this interactive session, attendees will learn:

  • The basics of a great presentation including slides to cover the science and business strategy
  • The qualities of a great presentation including how to be both succinct and specific

To prepare for the workshop, attendees can download and fill out the “Creating Your Elevator Pitch” worksheet by following the link below. This document is the first essential part of crafting effective presentation slides.

Please RSVP to Ryan Donovan, rdonovan@lavoiehealthscience.com

We look forward to seeing you.

 

One Great Day, Two Great San Diego Workshops

Monday, June 19; One Great Day, Two Great San Diego Workshops

Tales from the Biotech/Medtech Road and 15 Slides to Glory

Angus McQuilken, Vice President for Public Affairs, will be moderating a panel on June 19 at 9:00 am PT, Tales from the Road, at Redefining Early Stage Investments (RESI), San Diego.  The panel will feature four life science entrepreneurs who will share their experience with fundraising. The panel will focus on tactics, and the audience will leave with new tools and information to help them along with their own fundraising efforts. The panel includes Magda Marquet, Chairman & Co-Founder, AltheaDx; Michael Tippie, CEO, Lipidomics; Mike Moradi, Co-Founder & CEO, Sensulin; Joyce Lonergan, Founder & CEO, Mellitus.

Donna LaVoie, President & CEO, will be hosting a workshop on June 19 at 2:30 pm PT at BIO International in San Diego, “15 Slides to Glory: How to Create Your Company Presentation.” It will cover how to create an essential company presentation in just 15 slides. Attendees will participate in an interactive session to learn about the basics of effective public speaking, including the importance of avoiding information overload.  As preparation for this session, please download, read, and fill out, the brief worksheet linked below on “Creating Your Elevator Pitch,” the first essential part of crafting effective presentation slides. This session will include audience members sharing their elevator pitches and getting live feedback on which elements work well and which need improvement. WORKSHEET LINK: http://bit.ly/BIO-ElevPitch

 

Donna L. LaVoie to Deliver Workshop at BIO International on the LHS 15-Slide Presentation™

Donna L. LaVoie to Deliver Workshop at BIO International on the LHS 15-Slide Presentation™

How to Develop a Corporate Presentation in Just 15 Slides

Boston – June 5, 2017 – Donna L. LaVoie, president and CEO of LaVoieHealthScience (LHS), an award-winning integrated strategic communications agency focused on health and life science, will be presenting at BIO International in San Diego on June 19 at 2:30 p.m. PT. Donna will be delivering a workshop, “15 Slides to Glory: How to Create your Company Presentation,” the LHS trademarked process of creating a corporate deck in just fifteen slides.

“I am very happy to return to BIO International to lead this workshop on developing key message pillars to engage with stakeholders,” she said. “To run your business successfully you need clear and concise messaging, and the LHS 15-Slide Presentation™ helps to do just that.”

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

LaVoieHealthScience has worked with BIO to develop a thought leadership series of videos on public speaking covering The LHS 15-Slide Presentation™, Public Speaking Strategies for the CEO and Creating Your Elevator Pitch. More information on this series can be found here.

About LaVoieHealthScience
LaVoieHealthScience provides strategic communications, investor relations and public relations to build recognition and increase sales and value for health science innovations to improve humankind. The agency has received 28 awards over the past seven years in recognition of the work it has done for its health and science industry-leading clients. The agency ranks among the 2016 Inc. 5000 list of fastest growing private companies and among the Top 30 Independent Healthcare Firms as ranked by O’Dwyer’s PR.

###

Contact:
Beth Kurth
Vice President, Investor Relations
bkurth@lavoiehealthscience.com
617-374-8800 x106

LaVoieHealthScience Announces New PR Clients to its Roster

BOSTON, MA – March 23, 2017LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced it has signed new clients to its public relations client roster including BioAxone BioSciences, Inc.,

 “Our passion is to represent true innovators in the health and science fields,” said Donna L. LaVoie, President and CEO, LaVoieHealthScience.  “Our client companies are led by scientific and business visionaries who are shaping the way patients will be treated and making difference in healthcare delivery. We are delighted to expand our reach in biotechnology, medical device, and medical technology.” 

LaVoieHealthScience is leading a full array of integrated communications for these new clients including LHS Immersion®, The LHS Fifteen Slide Presentation®,  investor and corporate communications, investor and business development access, local and national media relations, digital and content development, thought leadership as well as social engagement programs.  The companies’ expertise includes:

  • BioAxone BioSciences, Cambridge, MA is committed to applying a deep understanding of  axon regeneration and neuronal signaling pathways to transform the lives of patients afflicted with neurotrauma or neurovascular disorder.
  • MicroPort Orthopedics, Burlington, MA,  is a medical device company that develops and manufactures knee and hip implants designed to help patients achieve full function faster. 
  • Major global pharmaceutical company, Cambridge MA, is exploring cutting-edge science and technology opportunities with relevance for dermatology.

About LaVoieHealthScience
LaVoieHealthScience partners with leading life science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides strategic communications, investor relations and public relations to build recognition and increase sales and value for health science innovations. The agency has received 28 awards over the past seven years in recognition of the work it has done for its health and science industry-leading clients.  In addition to clients listed above, LaVoieHealthScience represents leaders such as Cydan Development, Imara, NewLink Genetics, Biotechnology Innovation Organization, Newron Pharmaceuticals, Origenis, and other emerging health and science companies.

Contact:
Beth Kurth
Vice President, Investor Relations
LaVoieHealthScience
bkurth@lavoiehealthscience.com
617 374 8800, x106

Spotlight: Q&A with Michael Almstetter, CEO, Origenis

Michael Almstetter, CEO
Michael Almstetter, CEO

Q: What does Origenis do?
A: Origenis is creating small molecule drugs capable of penetrating the blood-brain barrier and therefore treating neurodegenerative diseases – commonly known as Central Nervous System, or CNS, diseases. Our technology-based drug design process develops faster, more specific compounds. I am pleased to note our platform has been validated through internal projects and external partners, and has yielded several patented drug candidates now in late stage clinical development since its application in 2005.

Q: What was your inspiration for founding Origenis? What do you hope to achieve?
A: Our goal is to fight neurodegeneration by breaking the vicious cycle that contributes to CNS diseases. That cycle includes microglia activation, which leads to neuro-inflammation, and then cell death, in turn contributing to microglia activation and so on. By inhibiting any of these phases of the cycle, Origenis can help regarding several chronic and acute neurodegenerative diseases such as Parkinson’s Disease, Alzheimer’s, dementia and Multiple Sclerosis as well as Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy.

Q: How does Origenis’ drug discovery platform work?
A: Origenis drug discovery platform has four major pillars: MOREsystem®, MolMind®, and Cippix® represent the proprietary technologies for the fast identification, seamless optimization and efficient synthesis of patentable new chemical entities. The pharmacological efficacy of our compounds is assessed and optimized with BRAINstorm™, the key technology for generating and optimizing brain penetrating compounds at Origenis.

Q: Sounds interesting, is there a competitive advantage?
A: Absolutely! With our leveraging unique chemistry capabilities we provide continual IP-protected new chemical entities. Our unique drug discovery process allows a faster and more specific development of compounds and delivers de-risked new chemical entities for partners, and of course for ourselves. As noted earlier, our platform has been validated not only through internal projects, but also with external partners and has yielded several patented drug candidates.

Q: Can you give us insight into current projects?
A: Origenis develops several, distinct small molecule drugs, which nicely cross the blood brain barrier with no need for a special formulation. These drugs act highly specifically on selected protein kinases responsible for microglia activation, neuronal cell death and neuroinflammation.

Our front-runner is our LRRK2 (Leucine Rich Repeat Kinase 2) therapeutic program. Inhibition of LRRK2 results in a significant decrease in neuronal damage. This opens the avenue for a first disease-modifying treatment in the field of Parkinson’s disease. Our LRRK2 lead drug candidate has outstanding compound properties in terms of potency and selectivity and an execellent brain penetration and PK profle. It should be mentioned that we were the first company to show in-vivo efficacy in an acute neuroegeneration model with our brain available LRRK2 inhibitor.

In addition to the therapeutic programs, Origenis also develops specific PET tracers – necessary tools to translate preclinical compounds into clinical drugs. These PET tracers are a huge strategic advantage in this highly competitive field. Origenis 18F-radiolabelled LRRK2-specific PET tracer, the only one available in the world. This represents the key differentiator in the LRRK2 field and opens a range of partnering and licensing options.

Q: Why is there so much excitement about LRRK2?
A: Two words: science and impact. There is now a deeper understanding of the science and a broader understanding of the impact. In terms of science, a mutation in LRRK2 has been identified as a genetic marker for Parkinson’s disease. In terms of the impact, we have people like Michael J. Fox who has the disease, and Google co-founder Sergey Brin who has the marker. Thus there is more interest from foundations, big pharma and others.

Q: Who else is on the Origenis leadership team?
A: Origenis was founded in 2005 by Michael Thormann, CSO, Andreas Treml, COO and myself. We previously worked together at a multinational biotech company, developing technologies and functioning as a business unit. We have a proven track record in drug design, compound synthesis and characterization. We are based in Munich, Germany and recently added CFO Thomas Loeser who brings financial and deal making expertise, in both Europe and the U.S.

Q: What is Origenis’ business strategy going forward?
A: Since we are already established as an R&D partner of choice, we have a track record of steady and profitable growth of R&D collaborations. That being said, we extended our business model towards faster value creation and are currently seeking up to €20 million for Series A financing to advance our internal pipeline.

We have full ownership of all projects, results and data packages. Our partnering strategy entails out-licensing assets from our significant IP and R&D portfolio and building partnering agreements with large pharmaceutical companies.

LaVoieHealthScience Awarded MarCom Gold for Oticon Opn™ Launch

Boston, Mass., – November 8, 2016 – LaVoieHealthScience (LHS), an integrated strategic communications agency focused on health and life science, announced today it has won a MarCom Gold Award in the product launch category for the agency’s work on the Opn™ launch on behalf of its client, Oticon, an advanced audiology and hearing aid technology industry leader.

LHS developed a stratified media campaign for the Oticon Opn™ launch in the US and secured coverage on high-profile national outlets including the New York Times and USA Today as well as multiple local media outlets in targeted markets. The campaign employs a Harris Poll QuickQuery® and creates robust multimedia content such as an infographic and videos to raise awareness on hearing health, build recognition for Opn™, and increase engagement with prospective customers.

“The LHS team is honored to be acknowledged for our work on the Oticon product launch by MarCom Awards. Oticon Opn™ is a breakthrough hearing aid shown to improve speech understanding for people with hearing loss,” said Donna L. LaVoie, President and CEO of LaVoieHealthScience. “The launch of Opn™ is Oticon’s biggest product launch in more than a decade, and we are excited to be involved in bringing this technology to tens of millions of Americans affected by hearing loss.”

The MarCom Awards is a creative competition for any individual or company involved in the concept, writing and design of print, visual, audio and web materials and programs. Entries come from corporate marketing and communication departments, advertising agencies, PR firms, design shops, production companies and freelancers. The MarCom awards are one of the largest of its kind in the world with over 6,000 entries every year.

About LaVoieHealthScience

LaVoieHealthScience partners with leading life science brands to build value for their companies, attract capital, and reach key stakeholders through integrated communications and marketing. The firm provides strategic communications, investor relations and public relations to build recognition and increase sales and value for health science innovations to improve humankind. The agency has received 28 awards over the past seven years in recognition of the work it has done for its health and science industry-leading clients. The agency ranks among the 2016 Inc. 5000 list of fastest growing private companies.

###

Contact
Beth Kurth
Vice President, Investor Relations
bkurth@lavoiehealthscience.com
617-374-8800 x106